Premaitha Health

The placing and subscription shares that are part of the offering are expected to start trading on the AIM market of the London Stock Exchange later this month.

The company plans to use parts of the proceeds from the offering to pay for the recent settlement with Illumina.

By early 2020, the UK company plans to develop a version of its Iona test that uses Illumina's sequencing technology.

Under the agreement, the companies plan to develop a customized solution that can be widely deployed for DNA sequencing.

The UK-based noninvasive prenatal testing firm also said that it has raised £2.5 million in funding through a share subscription.

The company is now seeking commercial partners in Brazil to make the Iona test available in the country.

Premaitha had been sued by Illumina for allegedly infringing on five patents related to noninvasive prenatal testing with its Iona test.

Pages

In Science this week: a CRISPR screen identifies sideroflexin 1 as a requisite component of one-carbon metabolism, and more.

Though many details have yet to be worked out, the draft deal for the UK's withdrawal from the EU is giving researchers some hints for what they can expect, Nature News says.

DNA testing has solved a 100-year-old mystery contained in the skull and teeth samples of a now-extinct monkey that once inhabited Jamaica, Gizmodo reports.

As the UN ponders a ban on gene drives, one malaria researcher says there are less dramatic ways to fight the disease in Africa than unleashing GM mosquitoes on a whole continent.